ABSTRACT: The objective of this study was to quantify and compare the contrast-enhancing properties of the anionic contrast agent ioxaglate/Hexabrix, and cationic contrast agent CA 4þ for biochemical and morphological characterization of the intervertebral disc (IVD) via mCT. Optimal contrast agent concentrations were determined by incubating rat lumbar IVDs in dilutions of Hexabrix-320 (20%, 30%, 40%, and 50%) and CA 4þ (10, 20, 30, and 40 mg I/ml). mCT imaging was performed at 70 kVp, 114 mA, and 250 ms integration time, 12 mm voxel size. The kinetics of contrast enhancement were quantified with cumulative incubations for 0.5, 1, 2, 12, 16, 20, and 24 h using both agents. Agreement in morphological quantification was assessed via serial scans of the same IVDs. Correlation of attenuation to glycosaminoglycan (GAG) content was determined by enzymatic digestion of IVDs, subsequent mCT imaging, and GAG quantification via dimethylmethylene blue assay. Forty percent Hexabrix and 30 mg I/ml CA 4þ were chosen as optimal concentrations. Hexabrix enabled greater delineation of the IVD from surrounding tissues, and CA 4þ had the lowest uptake in surrounding soft tissue. Twenty-four hour incubation was sufficient for >99% equilibration of both agents. A high level of agreement was observed in the quantification of IVD volume (ICC ¼ 0.951, r ¼ 0.997) and height (ICC ¼ 0.947, r ¼ 0.991). Both agents exhibited strong linear correlations between mCT attenuation and GAG content (Hexabrix: r ¼ À0.940; CA 4þ : r ¼ 0.887). Both agents enable biochemical and morphological quantification of the IVD via contrast-enhanced mCT and are effective tools for preclinical characterization. ß
Degenerative disc disease (DDD) is a common affliction of the intervertebral disc (IVD) that presents with morphological, mechanical, and biochemical changes. Currently, diagnosis of DDD is dependent on the use of imaging techniques such as radiography or magnetic resonance imaging (MRI) to detect degenerative morphological changes in the IVD. However, these morphological changes are typically not diagnosable until advanced progression of DDD, limiting treatment options and efficacy. Animal models have become essential to the study of DDD pathomechanisms and the development of improved modalities for disc characterization. Several small-animal models have been shown to share similar mechanical and biochemical properties with human IVDs, 1 and these models provide a means for observation of disease progression and development of novel diagnostic tools and treatment strategies.
Quantitative imaging is essential to the study of DDD. However, the use of small-animal models introduces some obstacles to frequently used imaging techniques. Although magnetic resonance imaging (MRI) techniques, such as delayed gadolinium enhanced MRI of cartilage (dGEMRIC), are viable methods to study the morphology of human cartilaginous tissues, resolutions achievable by MRI are typically insufficient to detect micron-level morphological changes in small-animal IVDs. Microcomputed tomography (mCT) offers much higher resolution, but is limited by the inherently low X-ray attenuation of soft tissues. To improve the visualization and characterization of soft tissues, several radiodensity-increasing contrast agents have been utilized in both orthopaedic and non-orthopaedic literature, including iodine-based (ioxaglate,2À9 iothalamate, 10 NaI, 11, 12 and CA 4þ [13] [14] [15] [16] [17] [18] [19] [20] ), and gadolinium-based contrast agents (gadopentetate, 11, 21 gadoteridol, 11, 21 and non-ionic gadodiamide 11 ). Equilibrium partitioning of an ionic contrast agent (EPIC)-mCT is a contrast-enhancing technique able to provide both morphological and biochemical information about tissues rich in sulfated glycosaminoglycans (GAGs).
2-6 EPIC-mCT is based on the electrostatic repulsion of the anionic contrast agent ioxaglate (Hexabrix, Guerbet LLC) by the anionic extracellular matrix (ECM) of cartilaginous tissues, affording spatial contrast enhancement inversely proportional to the concentration of negatively charged GAGs. Studies have utilized EPIC-mCT to image cartilaginous tissues in small animal models, including murine xiphoid, 22 femur [3] [4] [5] 8 and tibia, 9 and lapine femur. 2 Furthermore, the use of EPIC-mCT to characterize IVD degeneration following annular puncture and nucleotomy was recently described by Maerz et al. 23 It has been suggested that a cationic agent may provide better contrast enhancement due to a preferential affinity, rather than repulsion, of the agent in GAG-rich areas. 16 The iodinated, cationic contrast agent "CA 4þ " has been used in multiple studies to characterize the GAG content of cartilaginous tissues in animal models both ex vivo [13] [14] [15] [16] and in vivo. 20 CA 4þ -enhanced mCT attenuation has also been demonstrated to correlate to coefficient of friction and compressive modulus in murine tibiae, 19 bovine osteochondral plugs, 18 and human metacarpal articular cartilage. 17 To date, the use of CA 4þ or any other cationic contrast agent to characterize IVD morphology and biochemical content has not been demonstrated.
The implementation of high-resolution imaging techniques sensitive to both GAG content and morphology in preclinical models of IVD degeneration may lead to enhanced understanding of the pathomechanics of DDD. The relative efficacy of anionic and cationic contrast agents for ex vivo imaging of the IVD has not yet been determined. To this end, the purpose of this study was to quantify the contrast-enhancing properties of the anionic contrast agent ioxaglate/Hexabrix (i.e., EPIC-mCT), and the cationic contrast agent CA 4þ for biochemical and morphological characterization of the IVD.
METHODS

Contrast Agent Preparation
Stock Hexabrix 320 solution (320 mg I/ml, Fig. 1A ) was obtained from Guerbet, LLC (Bloomington, IN). Experimental dilutions of Hexabrix were made by percent dilution (v/v) in 0.01 M phosphate-buffered saline (PBS) and deionized H 2 O (dH 2 O) as necessary to approach a physiologically relevant osmolarity of 400 mOsm. CA 4þ (Fig. 1B ) was synthesized via a modified synthetic route adapted from Joshi et al. 16 Complete details of the synthesis and characterization of CA 4þ are available in the supplemental information. A stock solution of 50 mg I/ml CA 4þ was made by dissolving the lyophilized chloride salt of CA 4þ in dH 2 O and adjusting the pH to 7.4 using 5 M aqueous NaOH. The stock solution of CA 4þ was diluted to experimental concentrations in dH 2 O, with NaCl added as needed to adjust osmolarity to 400 mOsm as previously described. 16 Dilutions of both contrast agents used for experimentation were supplemented with protease inhibitors (Sigma-Aldrich, St. Louis, MO) and 1% penicillin-streptomycin with fungizone.
Specimen Preparation and mCT Imaging
According to an institutional animal care and use committeeapproved protocol for an unrelated study, skeletally mature, female Lewis rats were euthanized via CO 2 asphyxiation. Lumbar spines were dissected en bloc and frozen at À20˚C in saline-soaked towels. Immediately prior to experimentation, lumbar spines were thawed to room temperature, and individual IVDs with 1/3 of their cranial and caudal vertebral bodies were sectioned using a die grinder equipped with a cutting wheel.
Imaging was performed on a mCT imaging system (mCT-40, Scanco Medical AG, Br€ uttisellen, Switzerland) at 70 kVp, 114 mA, and 250 ms integration time with an isotropic resolution of 12 mm. IVD specimens were scanned in a custom sample holder containing humidifying silica beads to maintain a 70% humid environment.
Optimization of Contrast Agent Concentration
To determine the optimal contrast agent concentration for imaging of the rat IVD, four concentrations of each contrast agent were investigated based on preliminary experiments assessing the range of concentrations in which contrast enhancement is achieved without exceeding the attenuation of vertebral bone (i.e., resulting IVD attenuation of $1000-5000 HU). Aqueous solutions of 20%, 30%, 40%, and 50% Hexabrix (64, 96, 128, and 160 mg I/ml, respectively) and 10, 20, 30, and 40 mg I/ml CA 4þ were prepared, as described above. IVD specimens (L2/L3-L5/L6, n ¼ 4 per group) were immersed in contrast media for 24 h at room temperature, which was determined as a sufficient time point for equilibration in preliminary experimentation, lightly dabbed with a towel, and imaged with mCT. Using a custom 3-plane viewing interface in MATLAB (Mathworks Inc., Natick, MA), manual contouring was performed to segment representative volumes from the IVD, adjacent bone, and soft tissue. Normalized frequency distributions of mCT attenuation were generated for each tissue, and the percent overlap of the IVD attenuation spectrum with adjacent tissues were calculated. Furthermore, the mean attenuation of the IVD and its nucleus pulposus (NP) and (annulus fibrosis) AF, contrast uptake ratio (CUR), and contrast enhancement per mg of Iodine were calculated. CUR is a measure of preferential uptake or exclusion of ionic contrast agents. 15 Anionic agents have a CUR < 1, indicating exclusion from the tissue, whereas cationic agents have a CUR > 1, indicating affinity. Based on this optimization, 40% v/v Hexabrix and 30 mg I/ml CA 4þ were chosen for further experimentation.
Kinetics of Contrast Enhancement
The kinetics of contrast enhancement of Hexabrix and CA 4þ were assessed using a serial, time-dependent incubation experiment. IVD specimens (L2/L3-L5/L6, n ¼ 4 per group) were incubated in either 40% Hexabrix or 30 mg I/ml CA 4þ , and mCT imaging was performed after cumulative incubation periods of 0.5, 1, 2, 12, 16, 20, and 24 h. As 24 h was determined in preliminary experimentation to be sufficient for equilibration, it was used as the endpoint for the characterization. Utilizing a custom MATLAB 3-plane viewing interface, three-dimensional (3D) volumes of interest (VOIs) of IVD and NP tissue were outlined by a single observer using a semi-automated algorithm consisting of manual outlining of select axial slices, subsequent interpolation of the volume between these slices, and finally manual inspection and cleanup of the resultant VOIs. The AF VOI was derived as the subtraction of the NP VOI from the IVD VOI. Time-dependent attenuation of IVD, NP, and AF tissue was fitted to an increasing, first-order exponential decay function as described by Palmer et al. 2 for characterization of Hexabrix diffusion kinetics into articular cartilage. Time constants describing the diffusion rate were calculated for each sample. Diffusion rates of Hexabrix and CA 4þ into the IVD, NP, and AF were compared using paired t-tests matched by IVD level.
Morphological Characterization
To compare morphological characterization from imaging data obtained using each contrast agent, IVD specimens (L1/ L2-L5/L6, n ¼ 5) were incubated for 24 h in 40% Hexabrix, imaged using mCT as described above, rinsed for 24 h in 0.01 M PBS to facilitate full desorption of Hexabrix, incubated for 24 h in 30 mg I/ml CA 4þ , and reimaged. 3D VOIs of the IVD and NP were isolated from each scan as described above. Whole IVD and NP volume were calculated from these VOIs. IVD height maps were calculated at each level using a previously established algorithm, 23 and mean heights of the whole IVD and defined NP, lateral, anterior, and posterior zones ( Fig. 5B) were calculated. Agreement of morphologic measurement between contrast agents was assessed via the intraclass correlation coefficient (ICC) and Pearson's product-moment correlation coefficient. The slope of the linear regression (Hex/CA 4þ ) was analyzed to assess whether quantification of IVD volume or height was greater using one contrast agent versus the other. A slope larger than one indicated greater quantification using Hexabrix-enhanced samples, and a slope smaller than one indicated greater quantification using CA 4þ -enhanced samples.
Correlation Between Contrast-Enhanced mCT Attenuation and GAG Content
To quantify the relationship between IVD GAG content and contrast-enhanced attenuation using the two contrast agents, an in vitro enzymatic digestion experiment was undertaken. L3/L4 and L4/L5 IVDs were digested for 24 h at 37˚C in 0, 5, or 10 U/ml papain (Sigma-Aldrich), a proteolytic enzyme previously shown to induce GAG depletion. 24, 25 After enzymatic digestion, IVDs were incubated in 40% Hexabrix or 30 mg I/ml CA 4þ (n ¼ 4 per contrast agent per papain concentration) for 24 h and imaged using mCT. After imaging, each sample was rinsed for 20 h in PBS at room temperature to facilitate desorption of the contrast agent, meticulously dissected from the vertebral endplates using microscopic guidance, lyophilized, and weighed to obtain dry weights. IVDs were digested to completion in 1 ml of 50 mg/ml proteinase K for 20 h at 56˚C, followed by 90˚C for 10 min to inactivate proteinase K. Digest solutions were centrifuged to remove solid particulate, transferred to filter centrifuge tubes (EMD Millipore, Billerica, MA) and centrifuged to remove DNA and remaining tissue debris. The resulting solutions were diluted to 30% (v/v) in dH 2 O and analyzed using the 1,9-dimethylmethylene blue (DMMB) assay modified from the protocol by Farndale et al. 26 A standard curve consisting of 0-70 mg/ml chondroitin sulfate (Sigma-Aldrich) was used and all samples were run in triplicate.
RESULTS
Optimization of Contrast Agent Concentration
Frequency distributions of the IVD, bony endplates and perivertebral soft tissue attenuation imaged at different concentrations of Hexabrix and CA 4þ are shown in Figure 2 . Using both contrast agents, the dynamic range of IVD attenuation increases noticeably with increasing concentration, and this is particularly apparent for CA 4þ , where distinct attenuation peaks of the NP and AF begin to separate at 30 and 40 mg I/ml concentrations ( Fig. 2G and H) . The attenuation spectrum of the bony endplate remained relatively constant at all concentrations of both contrast agents, and at high concentrations, IVD and bony endplate attenuation spectra began to overlap for both contrast agents. The Hexabrix IVD attenuation spectrum exhibited significant overlap with soft tissue attenuation at low concentrations, with the peaks separating at higher concentrations. At 50% Hexabrix, soft tissue attenuation began to exceed the attenuation of the bony endplate (Fig. 2D) , whereas CA 4þ -enhanced soft tissue attenuation remains relatively low at all concentrations ( Fig. 2E-H (Fig. 3) were chosen to maximize the dynamic range of IVD attenuation while minimizing attenuation overlap with adjacent tissues and minimizing beam hardening due to highly attenuating soft tissue. Both contrast agents enable NP/AF distinction and visualization of substructural features within the NP (Fig. 3) . Characteristics of each chosen contrast agent are shown in Table 1 .
Kinetics of Contrast Enhancement
The kinetics of contrast agent equilibration of Hexabrix and CA 4þ are shown in Figure 4A -C. Hexabrix exhibited lower time constants (B) (i.e., more rapid diffusion) compared to CA 4þ in the IVD (p ¼ 0.07), NP (p ¼ 0.12), and AF (p ¼ 0.12), though differences were not statistically significant. After 24 h of contrast incubation, full equilibrium of both contrast agents CONTRAST-ENHANCED mCT OF THE IVD into the IVD was evident (Fig. 4D) , with each achieving above 99% of maximum attenuation. Following 24 h of contrast enhancement, delineation between NP and AF tissue, as well as spatial distributions and substructural features of both tissues, was observed using both contrast agents (Fig. 4D) .
Morphological Characterization
Representative height maps of all IVD levels are shown in Figure 5A . A high level of agreement between the two contrast agents was observed in the characterization of disc morphology (Fig. 5C ). The volume of the whole IVD was quantified nearly identically between Hexabrix and CA 4þ (ICC ¼ 0.951, r ¼ 0.997), and it was quantified only slightly greater using Hexabrix (linear regression slope ¼ 1.0046). The quantification of NP volume exhibited the lowest level of agreement between the two agents (ICC ¼ 0.819, r ¼ 0.815), and it was quantified to a greater extent using CA 4þ (linear regression slope ¼ 0.8369). IVD height was quantified with consistently high agreement between the two agents, with ICC values of at least 0.900 and r values of at least 0.972 (Fig. 5C ). Whole IVD height (linear regression slope ¼ 1.0284), . Using both contrast agents, IVD attenuation progressively increased with increasing contrast agent concentration. Soft tissue attenuation is dramatically increased with increasing concentration of Hexabrix. This is not observed with the use of CA 4þ , but a larger degree of spectra overlap is present between IVD attenuation and surrounding tissues using CA 4þ compared to Hexabrix. Figure 3 . Sagittal mCT images with false-color overlays of a contrast-enhanced IVD using 40% Hexabrix (A), and a contrast-enhanced IVD using 30 mg I/ml CA 4þ (B). Both contrast agents increase the attenuation profile of the IVD and provide intra-tissue contrast between the GAG-poor annulus fibrosus and the GAG-rich nucleus pulposus. Contrast-enhanced images demonstrate visual correlation with Safranin-O staining intensity on histologic images (i.e., histologic GAG distribution) (C). Furthermore, contrast enhancement enables visualization of features within the NP, namely a cell-rich, GAG-poor substructure at the center of the NP (C). NP height (linear regression slope ¼ 1.2145), and anterior height (linear regression slope ¼ 1.1749) were quantified higher using Hexabrix, and lateral height (linear regression slope ¼ 0.9110) and posterior height (linear regression slope ¼ 0.8127) were quantified higher using CA 4þ (Fig. 5C ).
Correlation Between Contrast-Enhanced mCT Attenuation and GAG Content
Compared to undigested IVDs, both 5 and 10 U/ml papain induced significant decreases in IVD GAG content in the Hexabrix group (5 U/ml: p ¼ 0.004; 10 U/ml: p < 0.001) and in the CA 4þ group (5 U/ml: p ¼ 0.002; 10 U/ml: . Diffusion occurred more rapidly in the AF compared to the NP, and Hexabrix generally equilibrated more rapidly than CA 4þ , though differences were not statistically significant. After 24 h, >99% of equilibrium of both contrast agents was achieved, and the NP and AF, as well as substructural features were clearly delineated (D). Dashed lines represent the 95% confidence intervals of the time constant B.
CONTRAST-ENHANCED mCT OF THE IVD p ¼ 0.002) (Fig. 6A ) There was no significant difference in GAG content between 5 U/ml papain-treated and 10 U/ml papain-treated IVDs in either group (Hexabrix: p ¼ 0.211; CA 4þ : p ¼ 0.922). Compared to undigested IVDs, papain induced significant increases in IVD attenuation using Hexabrix (5 U/ml: p < 0.001; 10 U/ml: p < 0.001) and decreases in IVD attenuation using CA 4þ (5 U/ml: p < 0.001; 10 U/ml: p < 0.001) (Fig. 6B ). There was no significant difference in IVD attenuation between 5 U/ml papain-treated and 10 U/ml papain-treated IVDs in either the Hexabrix group (p ¼ 0.462) or CA 4þ group (p ¼ 0.927). Axial contrast-enhanced mCT images demonstrate the increase and decrease in IVD attenuation in the Hexabrix ( Fig. 6D and E) and CA 4þ groups ( Fig. 6F and G) , respectively, and loss of NP detail and NP/AF contrast are evident.
There were strong linear relationships between GAG content and IVD attenuation in both the Hexabrix group (slope ¼ À114.9) and the CA 4þ group (slope ¼ 91.97) (Fig. 6C) . When the slope of the attenuation-GAG relationship was normalized by the iodine concentration of each contrast agent (mg I/ml), CA 4þ had a greater normalized slope (3.06 HU/GAG per mg I/ml) compared to Hexabrix (À0.89 HU/GAG per mg I/ml).
DISCUSSION
Advanced imaging techniques which can nondestructively provide morphological and biochemical information about the IVD are essential to understanding the pathomechanisms and potential treatments of DDD. Contrast-enhanced mCT (CE-mCT) has high spatial resolution and has already been described for the characterization of a variety of cartilaginous soft tissues, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] 23 making it a suitable imaging modality for small animal models of DDD. The present study characterized and compared the contrast-enhancing properties of the cationic contrast agent CA 4þ to Hexabrix in the mCT imaging of rat IVDs. We found that 30 mg I/ml of CA 4þ and 40% Hexabrix represent optimal concentrations for imaging of the IVD as they maximize the dynamic range of the IVD attenuation while minimizing imaging artifacts and attenuation spectra overlap with surrounding tissues. Although CA 4þ is electrostatically attracted to negatively charged GAGs, it equilibrated more slowly than Hexabrix, however both contrast agents reached 99% of maximum attenuation by 24 h of incubation. Both contrast agents exhibited strong, linear correlation between IVD GAG content and contrast-enhanced attenuation. There was a high level of agreement in morphological quantification of IVD volume and zonedependent IVD height between the two agents, although measurements performed on Hexabrixenhanced scans were consistently higher.
Unlike conventional tissue analysis techniques such as histology, CE-mCT provides a nondestructive modality for the 3D characterization of IVD morphology. 23 Both Hexabrix and CA 4þ enable detailed morphological characterization of the IVD, enabling distinction of NP/AF tissue boundaries as well as visualization of a condensed, notochordal cell-rich substructure within the NP (Fig. 3C) . The two agents exhibited a high level of agreement in the quantification of IVD volume and zone-dependent height in our study. Small differences were found in the determination of NP volume as it was consistently quantified lower using Hexabrix, likely due to superior visualization of the GAG-rich NP and NP/AF border using CA 4þ . Delineation of the outer AF border is challenging regardless of the contrast agent used, despite marked improvements over delineation of non-enhanced IVDs. Total AF volume was quantified only slightly higher using Hexabrix, which we attribute to the lack of contrast enhancement of the GAG-poor outer AF using CA 4þ . Using the entire segmented IVD volume and a semiautomated, zone-dependent height analysis previously developed by our group, 23 we demonstrated a high level of agreement in the quantification of IVD height between the two contrast agents, and neither agent consistently over-or under-quantified IVD height.
Overall, our results demonstrate that morphological assessment using either agent can be done with high accuracy.
Our data demonstrate that both Hexabrix and CA 4þ exhibit a strong linear relationship between contrastenhanced mCT attenuation and GAG content of the IVD. In articular cartilage, Bansal et al. 15 showed that CA 4þ significantly correlated to changes in GAG content while Hexabrix did not, however this is likely attributable to the much lower concentrations of both contrast agents (16 mg I/ml Hexabrix, 8 mg I/ml CA 4þ ) compared to those used in the present study (128 mg I/ml Hexabrix, 30 mg I/ml CA 4þ ). While 40% Hexabrix exhibited a greater absolute slope (attenuation vs. GAG content) compared to 30 mg I/ml CA 4þ , it contains a markedly greater amount of iodine (128 mg I/ml). When normalized by iodine concentration, CA 4þ exhibited a nearly threefold greater absolute slope (3.06 vs. À0.89 HU/ GAG per mg I/ml). As expected, the two contrast agents have CURs on opposite sides of one (Hexabrix: 0.326; CA 4þ : 1.82). A CUR value of one indicates that the concentration of contrast agent within the tissue is the same as within the contrast incubation media. Our results demonstrate 32.6% uptake (67.4% exclusion) of Hexabrix within the IVD, and 182% uptake of CA 4þ with respect to the attenuation of the contrast incubation media (i.e., the concentration of contrast agent within the media). A greater magnitude of deviation from a CUR of one indicates a greater sensitivity to GAG content, 15 and these CUR results, together with results from GAG-attenuation correlations, demonstrate an overall greater sensitivity to IVD GAG content with the use of CA 4þ . We performed an optimization experiment to determine the ideal concentration of each contrast agent in the setting of IVD imaging. Rather than attempting to use comparable iodine concentrations of each agent or attempting to minimize iodine concentration for in vivo application, we chose the concentration of each agent independently and aimed to fully optimize the efficacy of ex vivo characterization. To fully enable visualization, accurate segmentation, and sensitive biochemical characterization, the optimization must balance sufficient enhancement of the tissue-ofinterest, minimization of overlap of the attenuation spectra of adjacent tissues, and minimization of tomographic beam hardening artifact. Hexabrix exhibits a higher degree of uptake into the GAG-poor soft tissues surrounding the IVD (anterior and posterior longitudinal ligaments, muscle, etc). At higher concentrations, CONTRAST-ENHANCED mCT OF THE IVD starting with 50% Hexabrix, our data demonstrate increased overlap between IVD and bone attenuation, and soft tissue attenuation surpassing that of bone, exceeding 5000-8000 HU. The large amount of contrast agent in soft tissue at higher concentrations of Hexabrix exacerbates beam hardening artifact, necessitating a high-energy beam, the use of metal filters, software-based correction, or a combination of these. We found that 40% Hexabrix was the optimal concentration to maximize the dynamic range of IVD attenuation while still allowing segmentation of the IVD from both bone and soft tissue. CA 4þ -enhanced soft tissue exhibited minimal contrast enhancement and thus tissue overlap was minimized largely by increasing CA 4þ concentration, increasing the density spectrum of the IVD with minimal contrast agent uptake in either bone or the GAG-poor soft tissue surrounding the IVD. However, due to the inherently low GAG concentration of the outer AF, there is considerable density spectra overlap between the outer AF and surrounding soft tissue, which can potentially lead to underestimation of IVD volume. Overall, contrast enhancement with 30 mg I/ml CA 4þ results in more density spectra overlap with surrounding tissues than with 40% Hexabrix, but CA 4þ minimizes beam hardening artifact due to an inherently lower concentration of iodine atoms and reduced contrast agent uptake by peripheral tissues.
The kinetics of contrast enhancement of the two contrast agents were investigated using a serial incubation experiment. Our data show that 24 h was sufficient to achieve complete contrast enhancement using both contrast agents, as the IVD reached 99% of maximum attenuation by 24 h. Interestingly, even though CA 4þ is electrostatically attracted to negatively charged GAG-rich tissues, 13, 16 it did not exhibit a faster diffusion rate into the IVD. The diffusion of CA 4þ is likely dependent upon other factors such as molecular weight, solute size, and other biochemical interactions, and future studies may characterize its diffusion characteristics in greater detail. Based on our results, incubation times of <20 h may introduce motion artifact in applications involving the rat IVD due to incomplete diffusion equilibrium, and because of this relatively long incubation time, supplementation of contrast media with protease inhibitors and antibiotics/antimycotics is important to preserve the tissue state. Chemical fixation can be utilized to preserve tissue, but previous studies have shown that fixation affects contrast enhancement. 7, 23 This study is not without limitations. Any imaging modality is inherently limited by resolution and contrast. We employed an isotropic voxel size of 12 mm which we believe to be more than sufficient for contrast-enhanced imaging of the rat IVD, but studies assessing very small variations in IVD morphology and composition may require higher resolution. To characterize the kinetics of contrast enhancement, we employed a simple, first-order model of diffusion, as previously utilized to assess EPIC-mCT diffusion, 2 but this may be an oversimplification of the actual diffusion kinetics of Hexabrix and CA 4þ . Manual segmentations of the IVD were performed by an experienced researcher, but small error and subjectivity cannot be ruled out. The development of an automated segmentation scheme to consistently segment the IVD from contrastenhanced datasets may remove subjectivity and improve accuracy and consistency. Our DMMB assay results indicate that digested samples imaged with CA 4þ yielded a slightly higher GAG concentration than digested samples imaged with Hexabrix (Fig. 6C) , and this result may be due to a small interfering effect of residual CA 4þ on the DMMB assay. While all samples were rinsed prior to DMMB, we cannot rule out that a small amount of residual CA 4þ remained within the IVD. This study compared the contrast enhancing properties of an anionic contrast agent, Hexabrix, to a cationic contrast agent, CA 4þ , in mCT imaging of the IVD. Optimal contrast agent concentrations were determined for both Hexabrix (40% of Hexabrix 320) and CA 4þ (30 mg I/ml), and a minimum of 20 h of incubation are required to reach near-equilibrium diffusion. Both agents facilitate the quantification of IVD morphology and their relative contrast-enhanced attenuations demonstrate a highly linear relationship to IVD GAG content. Hexabrix-enhanced IVDs exhibited less attenuation spectra overlap with surrounding soft tissue compared to CA 4þ , resulting in a more defined IVD border to facilitate accurate segmentation. However, Hexabrix demonstrated a higher degree of uptake into the perivertebral, GAG-poor soft tissues, exacerbating potentially detrimental beam hardening artifact. CA 4þ exhibited greater overall sensitivity to IVD GAG content, as demonstrated via CUR and HU/GAG slope normalized by iodine content, but it had slightly slower equilibration kinetics compared to Hexabrix. Future studies assessing the pathomechanisms or potential therapeutic treatments of DDD can utilize either of these contrast agents to facilitate ex vivo contrastenhanced mCT for 3D, quantitative characterization of the IVD.
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